Trials / Completed
CompletedNCT02504645
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- ImmuPharma · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This current Phase 3 study will evaluate the efficacy and safety of administration of subcutaneous (sc) IPP-201101 in patients with active SLE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IPP-201101 | |
| DRUG | Placebo | |
| OTHER | Standard of Care |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2015-07-22
- Last updated
- 2019-04-11
- Results posted
- 2019-04-11
Locations
30 sites across 8 countries: United States, Czechia, France, Germany, Hungary, Mauritius, Poland, Puerto Rico
Source: ClinicalTrials.gov record NCT02504645. Inclusion in this directory is not an endorsement.